I agree that this site is using cookies. You can find further informations here.
X
Bittner, VA
16  results:
Search for persons X
?
1

Factors associated with time to initiation of a PCSK9 inhib..:

McKinley, EC ; Bittner, VA ; Brown, TM...
Journal of Clinical Lipidology.  16 (2022)  1 - p. 75-82 , 2022
Link: https://doi.org/10.1016/..
 
?
2

Transiently achieved very low LDL-cholesterol levels by sta..:

Schwartz, GG ; Szarek, M ; Bhatt, DL...
Eur Heart J.  , 2023
Link: https://qmro.qmul.ac.uk/..
 
?
3

Transiently achieved very low low-density lipoprotein chole..:

Schwartz, GG ; Szarek, M ; Bhatt, DL...
10044/1/103375.  , 2023
Link: http://hdl.handle.net/10..
 
?
4

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients ..:

Schwartz, GG ; Szarek, M ; Bittner, VA...
J Am Coll Cardiol.  , 2021
Link: https://qmro.qmul.ac.uk/..
 
?
5

Lipoprotein(a) lowering by alirocumab reduces the total bur..:

Szarek, M ; Bittner, VA ; Aylward, P...
European Heart Journal.  , 2020
Link: http://hdl.handle.net/10..
 
?
6

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular R..:

Bittner, VA ; Szarek, M ; Aylward, PE...
15583597.  , 2020
Link: https://doi.org/10.1016/..
 
?
7

Alirocumab in Patients With Polyvascular Disease and Recent..:

Jukema, JW ; Szarek, M ; Zijlstra, LE (Laurien)...
Jukema , JW , Szarek , M , Zijlstra , LE , de Silva , HA , Bhatt , DL , Bittner , VA , Simoons , M , Sijbrands , E J G , Picault , P & Zobouyan , I 2019 , ' Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial ' , Journal of the American College of Cardiology , vol. 74 , no. 9 , pp. 1167-1176 . https://doi.org/10.1016/j.jacc.2019.03.013.  , 2019
Link: https://pure.eur.nl/en/p..
 
?
8

Effect of alirocumab on mortality after acute coronary synd..:

Steg, PG ; Szarek, M ; Bhatt, DL...
Circulation.  , 2019
Link: http://hdl.handle.net/10..
 
?
9

Risk categorization using New American College of Cardiolog..:

Roe, MT ; Li, QH ; Bhatt, DL...
Circulation.  , 2019
Link: http://hdl.handle.net/10..
 
?
10

Risk Categorization Using New American College of Cardiolog..:

Roe, MT ; Li, QH ; Bhatt, DL...
Roe , MT , Li , QH , Bhatt , DL , Bittner , VA , Diaz , R , Goodman , SG , Harrington , RA , Jukema , JW , Lopez-Jaramillo , P , Lopes , RD , Louie , MJ , Moriarty , PM , Szarek , M , Vogel , R , White , HD , Zeiher , AM , Simoons , M , Sijbrands , E J G , Baccara-Dinet , M , Steg , G & Schwartz , GG 2019 , ' Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes ' , Circulation , vol. 140 , no. 19 , pp. 1578-1589 . https://doi.org/10.1161/circulationaha.119.042551.  , 2019
Link: https://pure.eur.nl/en/p..
 
?
11

Effects of alirocumab on types of myocardial infarction: in..:

White, HD ; Steg, PG ; Szarek, M...
EUROPEAN HEART JOURNAL.  , 2019
Link: https://qmro.qmul.ac.uk/..
 
?
12

Effects of alirocumab on types of myocardial infarction: in..:

White, HD ; Steg, PG ; Szarek, M...
White , HD , Steg , PG , Szarek , M , Bhatt , DL , Bittner , VA , Diaz , R , Edelberg , JM , Erglis , A , Goodman , SG , Hanotin , C , Harrington , RA , Jukema , JW , Lopes , RD , Mahaffey , KW , Moryusef , A , Pordy , R , Roe , MT , Sritara , P , Tricoci , P , Simoons , M , Sijbrands , E J G , Zeiher , AM & Schwartz , GG 2019 , ' Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial ' , European Heart Journal , vol. 40 , no. 33 , pp. 2801-2809 . https://doi.org/10.1093/eurheartj/ehz299.  , 2019
Link: https://pure.eur.nl/en/p..
 
?
13

Effects of alirocumab on types of myocardial infarction: in..:

White, HD ; Steg, PG ; Szarek, M...
European Heart Journal.  , 2019
Link: http://hdl.handle.net/10..
 
?
14

Effectiveness of Ultraviolet-C Disinfection on Hospital-Ons..:

Goto, Michihiko ; Hasegawa, Shinya ; Balkenende, Erin C...
Clinical Infectious Diseases.  76 (2022)  2 - p. 291-298 , 2022
Link: https://doi.org/10.1093/..
 
?
15

Phase 1/2a study of the malaria vaccine candidate apical me..:

Spring, MD ; Cummings, JF ; Ockenhouse, CF...
Spring , MD , Cummings , JF , Ockenhouse , CF , Dutta , S , Reidler , R , Angov , E , Bergmann-leitner , E , Stewart , VA , Bittner , S , Juompan , L , Kortepeter , MG , Nielsen , R , Krzych , U , Tierney , E , Ware , LA , Dowler , M , Hermsen , CC , Sauerwein , RW , de Vlas , S , Ofori-Anyinum , O , Lanar , DE , Williams , JL , Kester , KE , Tucker , K , Shi , M , Malkin , E , Long , C , Diggs , CL , Soisson , L , Dubois , MC , Ballou , WR , Cohen , J & Heppner , DG 2009 , ' Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A ' , PLoS One (print) , vol. 4 , no. 4 , pp. 5254-5254 . https://doi.org/10.1371/journal.pone.0005254.  , 2009
Link: https://pure.eur.nl/en/p..
 
1-15